Escitalopram and Depression in Elderly Alzheimer's Patients

Phase 3

Terminated

• Conditions: Depressive Disorder

• Registration Number: NCT00488670
• Lead Sponsor: University of British Columbia

Brief Summary

To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression.

Detailed Description

This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.

Study Timeline

• Study First Submitted: 2007-06-18
• Study First Submitted QC: 2007-06-19
• Study First Posted: 2007-06-20
• Study Start: 2010-12
• Status Verified: 2011-06
• Primary Completion: 2011-06
• Study Completion: 2011-06
• Last Update Submitted: 2011-06-02
• Last Update Posted: 2011-06-06

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• > 50 years
• Male & female
• Alzheimer's disease
• Depressive episode

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.

Secondary Outcome Measures

Name	Time	Method
Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study

Trial Locations

Locations (2)

Mt. St. Joseph's Hospital; 🇨🇦 Vancouver, British Columbia, Canada

Vancouver General Hospital; 🇨🇦 Vancouver, British Columbia, Canada